Between 2021 & 2024, 2.3% Of Eligible Consumers With Obesity Were Prescribed A GLP-1 Medication

About 2.3% of adults with obesity have been prescribed semaglutide (Wegovy) or tirzepatide (Zepbound) glucagon-like peptide-1 (GLP-1) medications for obesity after the medications were approved by the U.S. Food and Drug Administration (FDA), a study has found. The medications are intended for use by people with a body mass index (BMI) of 30 or a BMI of 27 or greater if the person has at least one obesity-related comorbidity. The researchers said the low prescription rate likely indicates system-level access barriers and consumer-level demand barriers, including narrow eligibility, limited insurance coverage, and . . .